EIMFS is characterized by nearly continuous seizures involving multiple independent areas of both hemispheres with arrested psychomotor development. It is an age-dependent, often overlooked syndrome among the epileptic encephalopathies that can occur within the first 6 months of life [7]. It may therefore be included among epileptic encephalopathies, together with others beginning in the same period, such as early infantile epileptic encephalopathy, early myoclonic encephalopathy, and infantile spasms [8]. The clinical manifestations of children with EIMFS are characterized by migrating and focal seizures, with an onset peak from 40 days to 3 months. Symptoms can manifest on EEG readings as diffuse slow waves in the background, multifocal discharge with or without spastic between episodes, typical or atypical hypsarrhythmia and never a suppression burst pattern [3]. EIMFS has no specific neuroimaging changes, and the neuroimaging abnormalities reported in the current literature include delayed myelination, abnormal signals in the basal ganglia, dysplasia in the corpus callosum, diffuse brain atrophy, microcephaly, multiple cortical developmental malformations with multiple cerebellar gyri, focal cortical dysplasia, and hippocampal sclerosis [2, 8, 9]. We described the phenotype spectrum of 36 patients with EIMFS in this study. All patients had clinical seizure migration associated with a significant impact on development. We identified several key phenotypic features that have only been rarely reported in the EIMFS phenotypic spectrum: 11 (11/36, 30.6%) patients had suspected in utero seizures with postnatal seizures described between 4 hours and 3 days, 8 (8/36, 22.2%) patients had epileptic spasms, 7 (7/36, 19.4%) had a burst-suppression pattern in EEG activity, 1 patient had congenital disorder of glycosylation—type Ik, 1 patient had Menkes disease, 3 patients had intracranial infection, 1 patient had inguinal hernia, 1 patient had intracranial hemorrhage, 1 patient had premature disease, 10 patients had congenital heart disease (open foramen ovale, patient ductus arteriosus), and 8 patients had a perinatal history (pneumonia, HIE, intrauterine distress). Furthermore, it is mostly believed that the etiology of EIMFS is caused by genetic mutations [7]. According to our etiological analysis, the genetic etiology accounted for 17/36 cases, and brain injury accounted for 17/36 cases, including 1 case of EIMFS caused by hypoxic-ischemic encephalopathy (HIE); hence, HIE sequelae can also lead to EIMFS. Analysis of etiology and prognosis results suggests that structural causes may be related to poor prognosis. Our data expand the clinical phenotype of EIMFS.
We describe the genotypic spectrum of 17 patients with EIMFS. We highlight the extensive genetic heterogeneity of EIMFS, which is similar to that in other epilepsy syndromes, such as infantile spasms (West syndrome) and Lennox-Gastaut syndrome, but with a considerably higher yield on current testing. We identified the etiology in 47.2% of our cohort, including 6 novel EIMFS genes. The most commonly involved genes were KCNT1 (8.3%) and SCN2A (16.7%), together explaining 25.0% of EIMFS cases. Among the 3 patients with KCNT1 gene mutations, the mutation sites of 1 patients were classified as a variant of unknown significance (VUS) by the American College of Medical Genetics (ACMG), and among the 6 patients with SCN2A gene mutations, the mutation site of 1 patient was classified as a VUS by the ACMG. However, according to the analysis of the clinical phenotypes and responses to drug therapy of the patients, we still believed that KCNT1 and SCN2A were the pathogenic genes of patients. This pattern differs from that reported in patients with neonatal-onset developmental and epileptic encephalopathy [10], including Ohtahara syndrome [11], for which KCNQ2 and SCN2A are most common. These studies highlight the importance of classifying a patient's epilepsy syndrome, which influences genetic testing and interpretation [12]. Epileptic spasms have only been rarely reported in EIMFS patients [2]. In this series, 8/36 patients (22.2%) had epileptic spasms, including those with KCNT1, SCN2A, SCN1A, DOCK6 and PCDH19 variants. Epileptic spasms are a hallmark of CDKL5 encephalopathy, but EIMFS had not been previously described in this disease. Whether other genes predispose patients with EIMFS to epileptic spasms will require studies with large cohorts to enable phenotype-genotype correlation.
The PNPO gene encodes pyridoxine 5-prime-phosphate oxidase, and the maintenance of optimal pyridoxal 5-prime-phosphate levels in the brain is important in many neurologic disorders in which neurotransmitter metabolism is disturbed, which is associated with autosomal recessive pyridoxamine 5'-phosphate oxidase deficiency [13]. The PNPO gene was EIMFS-related genes reported in previous literature. In our study cohort, although the mutation sites of the gene were classified as VUS by the ACMG, taking into account the analysis of the clinical phenotypes and responses to drug therapy of the patient, we still believed that PNPO was the pathogenic genes of patients.
We discovered 6 novel EIMFS genes in our cohort - de novo PCDH19; paternal ALDH7A1, DOCK6, PRRT2 and ALG1; and maternal ALDH7A1, ATP7A, DOCK6 and ALG1 - encoding a wide range of proteins. These genes have not been described in patients with EIMFS, but they have been associated with other neurological diseases.
Considering the PCDH19 gene first, most of the PCDH19 gene variants resulted in protein termination and nonsense-mediated decay and affected PCDH19 through impaired calcium binding, which is associated with X-linked early infantile epileptic encephalopathy-9 (EIEE-9) in females [14]. Considering that one of our patients was a female and had a de novo mutation of the PCDH19 gene, which is consistent with the X-linked genetic classification and the common clinical phenotype of spasms seizure and delayed motor development, the software predicted the likely pathogenicity of the mutation; thus, these findings suggest that the PCDH19 gene could be associated with EIMFS.
The ALDH7A1 gene encodes an aldehyde dehydrogenase that is an alpha-aminoadipic semialdehyde dehydrogenase in the pipecolic acid pathway of lysine catabolism, which is associated with autosomal recessive pyridoxine-dependent epilepsy [15]. Considering that some of our patients had paternal and maternal mutations of the ALDH7A1 gene, which is consistent with the autosomal recessive genetic classification and the common clinical phenotype of seizures, delayed motor development and effective treatment with vitamin B6, the software predicted the likely pathogenicity of the mutation; thus, these findings suggest that the ALDH7A1 gene could be associated with EIMFS.
DOCK6 belongs to subfamily C of the DOCK family and has a role in remodeling the actin cytoskeleton by functioning as a GEF for both CDC42 and RAC1 [16], which is associated with autosomal recessive Adams-Oliver syndrome-2. Adams-Oliver syndrome is a multiple congenital anomaly syndrome that is characterized by aplasia cutis congenita (ACC) as well as terminal transverse limb defects (TTLD) in addition to variable involvement of the brain, eyes, and cardiovascular system [17]. Although one of our patients had maternal and paternal mutations of the DOCK6 gene, which is consistent with the autosomal recessive genetic classification, and the software predicted the likely pathogenicity of the mutation, the patient lacked the typical clinical phenotype of Adams-Oliver syndrome-2. Therefore, we could not determine whether the DOCK6 gene was the causative gene of EIMFS, and further data are needed for verification.
The PRRT2 gene encodes proline transmembrane protein 2 and is involved in signal transduction between neurons. PRRT2-associated paroxysmal movement disorders (PRRT2-PxMD) include autosomal dominant genetic paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), paroxysmal kinesigenic dyskinesia with infantile convulsions (PKD/IC), and hemiplegic migraine (HM). The characteristics of BFIE include early onset, cluster seizures that could be self-healing or that respond well to the treatment of sodium channel blockers, and normal development. In addition, PRRT2 pathogenic variants have been identified in other childhood-onset movement disorders and different types of seizures, suggesting that the understanding of the spectrum of PRRT2-PxMD is still evolving [18]. The patient with this mutation in our cohort was very interesting. He presented with very frequent cluster seizures when he was 3 months old, video-EEG demonstrated migrating focal seizures and typical background characteristics of EIMFS, and he experienced obvious cognitive retardation after the onset of epilepsy. He achieved seizure-free status after the administration of oxcarbazepine, and follow-up showed normal cognitive development. The patient had a paternal mutation of the PRRT2 gene—his father had symptoms of dystonia in his youth—and the software predicted the likely pathogenicity of the mutation. We considered that the PRRT2 gene was the causative gene of EIMFS, and further data were needed for verification.
In the 10th patient, two pathogenic genes were detected simultaneously, namely, WWOX and ATP7A. The clinical phenotypes reported in the literature were X-linked Menkes disease, occipital horn syndrome, distal spinal muscular atrophy 3, epileptic encephalopathy, early infantile 28, esophageal squamous cell carcinoma, somatic and spinocerebellar ataxia, and autosomal recessive 12, which theoretically can cause epileptic encephalopathy [19–23]. This patient also had a significant decrease in blue copper protein, had hair and skin color changes and could have been diagnosed with Menkes disease. WWOX conformed to the genetic classification. One of the two mutation sites was a pathogenic mutation, and the other was a VUS. We could not confirm whether it was a copathogenic gene.
The ALG1 gene encodes mannosyltransferase I (MT I). The biosynthesis of lipid-linked oligosaccharides is highly conserved among eukaryotes and is catalyzed by 14 glycosyltransferases in an ordered stepwise manner. MT I catalyzes the first mannosylation step in this process [24]. The gene variants can result in autosomal recessive congenital disorder of glycosylation type Ik [25, 26]. The characteristics of congenital disorder of glycosylation type Ik includes feeding problems and diarrhea, profound hypoproteinemia with massive ascites, muscular hypertonia, seizures refractory to treatment, recurrent episodes of apnea, cardiac and hepatic involvement and coagulation anomalies [27]. The clinical characteristics of this patient were consistent with the above core symptoms, the genetic results were consistent with the law of autosomal recessive inheritance, and the software predicted the likely pathogenicity of the mutation. We considered the ALG1 gene to be a newly pathogenic gene of EIMFS.
Most patients with EIMFS are refractory to AEDs, but some have shown good progression or a near satisfactory response to treatment. The AEDs used alone or in combination with one another that may achieve seizure control or reduction are potassium bromide, levetiracetam, ACTH, stiripentol, clonazepam, and rufinamide [28]. Mikati et al. reported that quinidine is effective in the treatment of patients with KCNT1 gene mutations in EIMFS [29]. At present, there are few literature reports on the use of corresponding effective drug treatments for patients with different EIMFS gene mutations. In our cohort, we determined that vitamin B6 could allow patients with ALDH7A1 and PNPO mutations to achieve seizure-free status. Oxcarbazepine was effective for patients with SCN2A, ATP7A+WWOX, and PRRT2 mutations. One of the patients with a maternal SCN2A heterozygous mutation was treated with oxcarbazepine; subsequently, the patient’s convulsions were controlled. The patient’s mother had a normal heterozygote phenotype, which was consistent with the pathogenesis of autosomal dominant inheritance (incomplete penetrance). ACTH was partly effective for patients with DOCK6 mutations who had spasms and hypsarrhythmia.
While seizure outcomes and developmental prognoses are generally poor in EIMFS, there are rare reports of mildly affected patients [30]. In our study cohort, the incidence of poor prognosis was also relatively high; 6/36 (16.7%) patients died, and the related pathogenic genes were KCNT1, SCN1A, ALG1. 14/36 (38.9%) patients had severe retardation, and the genes for ineffective seizure control and severe retardation included KCNT1, SCN2A, WWOX and ATP7A. The results indicated that the related pathogenic genes KCNT1, SCN1A, ALG1, SCN2A, WWOX and ATP7A may be associated with ineffective seizure control and poor prognoses. While all patients experienced refractory epilepsy early in the course of the disease, 3/36 (8.3%) patients had normal mental and motor development. Genes associated with seizure-free, mild-moderate retardation or normal of mental and motor development included PRRT2, SCN2A, ALDH7A1, PCDH19 and PNPO.
In addition, we compared the association of MRI abnormalities, hypsarrhythmia and burst suppression in EEG with poor prognosis. The results found that patients with EIMFS characterized by abnormal MRI, hypsarrhythmia and burst suppression in EEG have a higher incidence of ineffective seizure control, severe retardation and a higher mortality rate. The results suggest that EIMFS patients who present with abnormal MRI, hypsarrhythmia and burst suppression in EEG may be associated with ineffective seizure control and poor prognosis. We need to further expand the sample to analyze and confirm these correlations.